CareDx
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare provider...
Latest News
10 days ago · businesswire.com
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the award of inducement grants. On November 5, 2026, as an inducement material to acceptance of employment with CareDx, 21 new employees were awarded restricted stock units (RSUs) for an aggregate of 33,375 shares of common stock. The RSUs will vest over four years, with 25% of the RSUs vesting on the first anniver.
11 days ago · zacks.com
CareDx (CDNA) Upgraded to Strong Buy: Here's What You Should KnowCareDx (CDNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
14 days ago · zacks.com
CareDx Q3 Earnings Call Highlights Raised '26 Outlook & Testing GrowthCDNA raises its 2026 revenue and profit outlook as transplant testing demand and NavDx growth accelerate, with new molecular diagnostics set for 2027 launches.
14 days ago · businesswire.com
CareDx Announces Third KOAR Analysis Published in TransplantationBRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the publication of a new analysis from the Kidney Allograft Outcomes AlloSure Registry (KOAR), a landmark multicenter study, in the journal Transplantation. The third manuscript from KOAR investigated the correlation between early post-transplant AlloSure Kidney donor-derived cell-free DNA (dd-cfDNA) levels and thr.
17 days ago · fool.com
Why CareDx Stock Soared TodayCareDx is a leader in the fast-growing field of medical diagnostics. The company is working to bring its non-invasive tests to new markets.
18 days ago · seekingalpha.com
CareDx, Inc. (CDNA) Q3 2026 Earnings Call TranscriptCareDx, Inc. (CDNA) Q3 2026 Earnings Call Transcript
18 days ago · marketbeat.com
What CareDx (CDNA) Said on Its Q3 Earnings CallCareDx NASDAQ: CDNA reported third-quarter 2026 revenue growth of 39% as testing volumes increased, driven by its transplant business and the addition of Specialty Oncology testing following the July acquisition of Naveris.
18 days ago · zacks.com
CareDx (CDNA) Surpasses Q3 Earnings and Revenue EstimatesCareDx (CDNA) came out with quarterly earnings of $0.7 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.28 per share a year ago.
22 days ago · zacks.com
CareDx to Report Q3 Earnings: Transplant Testing Growth in FocusCareDx's Q3 earnings are in focus as transplant testing growth, stronger reimbursement and oncology expansion drive revenue prospects despite potential margin pressures.
26 days ago · businesswire.com
CareDx Announces New KOAR Data Linking Elevated AlloSure® Kidney to Nearly 3-Fold Higher Risk of Adverse Graft Outcomes in Patients with Borderline Rejection or TCMR at ASN Kidney Week 2026BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today highlighted data featuring AlloSure® Kidney donor-derived cell-free DNA (dd-cfDNA) being presented at the American Society of Nephrology (ASN) Kidney Week 2026, taking place October 22–25 in Denver, Colorado. The findings address several persistent challenges in kidney transplant management: determining the significance of a.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove CDNA